Myriad Genetics is a molecular diagnostics company founded in 1991 that discovers, commercializes, and performs genetic tests to assess disease risk, diagnose conditions, track disease progression, and inform treatment decisions. The company has performed millions of tests across six medical specialties through four primary divisions: Myriad Women's Health, Myriad Oncology, Myriad Neuroscience, and Myriad Urology.
The company's core offerings span hereditary cancer testing, oncology diagnostics, prenatal screening, and pharmacogenomics. Its flagship products include myRisk Hereditary Cancer Test, myChoice CDx (a companion diagnostic for ovarian cancer), GeneSight (a pharmacogenomic test for mental health medication selection), and prenatal genetic screening tests. These tests are designed to detect hereditary cancers, prenatal conditions, oncological issues, and mental health-related genetic factors.
Myriad positions itself as a pioneer in molecular diagnostics with over three decades of operational history. The company's stated purpose is to empower individuals with genomic insights and enable healthcare providers to deliver personalised care that improves patient outcomes while reducing healthcare costs.
